UK markets open in 7 hours 42 minutes

23andMe Holding Co. (ME)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5440+0.0309 (+6.02%)
At close: 04:00PM EDT
0.5265 -0.02 (-3.22%)
After hours: 07:01PM EDT

23andMe Holding Co.

349 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 938 6300

IndustryDiagnostics & Research
Full-time employees

Key executives

NameTitlePayExercisedYear born
Ms. Anne WojcickiCo-Founder, CEO, President & Chair of the Board62.92kN/AN/A
Mr. Eli FryVice President of OperationsN/AN/AN/A
Mr. Guy ChayounVP, Interim General Counsel & Corporate SecretaryN/AN/AN/A
Ms. Katie WatsonVice President of CommunicationsN/AN/A1978
Mr. Jonathan WardChief Marketing OfficerN/AN/AN/A
Mr. Reza Afkhami M.B.A.Chief Corporate Development OfficerN/AN/AN/A
Ms. Savita PillaiVice President of PeopleN/AN/AN/A
Dr. Jennifer LowHead of Therapeutics DevelopmentN/AN/A1969
Mr. Kent HillyerVice President of Consumer OperationsN/AN/A1968
Mr. Daniel ChuChief Product OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

Corporate governance

23andMe Holding Co.’s ISS governance QualityScore as of 1 May 2024 is 9. The pillar scores are Audit: 3; Board: 8; Shareholder rights: 10; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.